163 related articles for article (PubMed ID: 9862757)
41. Cytochalasin modulation of nicotinic cholinergic receptor expression and muscarinic receptor function in human TE671/RD cells: a possible functional role of the cytoskeleton.
Bencherif M; Lukas RJ
J Neurochem; 1993 Sep; 61(3):852-64. PubMed ID: 8360687
[TBL] [Abstract][Full Text] [Related]
42. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration.
Glick SD; Maisonneuve IM; Kitchen BA; Fleck MW
Eur J Pharmacol; 2002 Mar; 438(1-2):99-105. PubMed ID: 11906717
[TBL] [Abstract][Full Text] [Related]
43. Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors.
Badio B; Padgett WL; Daly JW
Mol Pharmacol; 1997 Jan; 51(1):1-5. PubMed ID: 9016339
[TBL] [Abstract][Full Text] [Related]
44. Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells.
Beerepoot P; Lam VM; Salahpour A
J Biol Chem; 2016 Oct; 291(42):22053-22062. PubMed ID: 27555326
[TBL] [Abstract][Full Text] [Related]
45. What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders.
Straub CJ; Rusali LE; Kremiller KM; Riley AP
J Med Chem; 2023 Jan; 66(1):107-121. PubMed ID: 36440853
[TBL] [Abstract][Full Text] [Related]
46. (±)-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban).
Lapinsky DJ; Aggarwal S; Nolan TL; Surratt CK; Lever JR; Acharya R; Vaughan RA; Pandhare A; Blanton MP
Bioorg Med Chem Lett; 2012 Jan; 22(1):523-6. PubMed ID: 22119468
[TBL] [Abstract][Full Text] [Related]
47. Phencyclidine inhibition of the acetylcholine receptor: measurement of cation flux in a sympathetic neuronal cell line using 22Na+ and spectroscopic detection of Cs+.
Sachs AB; Leprince P; Karpen JW; Pasquale EB; Abood LG; Hess GP
Arch Biochem Biophys; 1983 Sep; 225(2):500-4. PubMed ID: 6625597
[TBL] [Abstract][Full Text] [Related]
48. Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones.
Sutton C; Williams EQ; Homsi H; Beerepoot P; Nazari R; Han D; Ramsey AJ; Mash DC; Olson DE; Blough B; Salahpour A
Front Cell Neurosci; 2022; 16():832536. PubMed ID: 35614973
[TBL] [Abstract][Full Text] [Related]
49. Antidepressants for smoking cessation.
Hajizadeh A; Howes S; Theodoulou A; Klemperer E; Hartmann-Boyce J; Livingstone-Banks J; Lindson N
Cochrane Database Syst Rev; 2023 May; 5(5):CD000031. PubMed ID: 37230961
[TBL] [Abstract][Full Text] [Related]
50. Stereoselective Metabolism of Bupropion to Active Metabolites in Cellular Fractions of Human Liver and Intestine.
Bamfo NO; Lu JB; Desta Z
Drug Metab Dispos; 2023 Jan; 51(1):54-66. PubMed ID: 35512805
[TBL] [Abstract][Full Text] [Related]
51. Disruption of the cholinergic anti-inflammatory response by R5-tropic HIV-1 protein gp120
Ríos SC; Colón Sáez JO; Quesada O; Figueroa KQ; Lasalde Dominicci JA
J Biol Chem; 2021; 296():100618. PubMed ID: 33811859
[TBL] [Abstract][Full Text] [Related]
52. Antidepressants for smoking cessation.
Howes S; Hartmann-Boyce J; Livingstone-Banks J; Hong B; Lindson N
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD000031. PubMed ID: 32319681
[TBL] [Abstract][Full Text] [Related]
53. The Response of Ventral Tegmental Area Dopaminergic Neurons to Bupropion: Excitation or Inhibition?
Sadighparvar S; Tale F; Shahabi P; Naderi S; Ghaderi Pakdel F
Basic Clin Neurosci; 2019; 10(4):281-304. PubMed ID: 32231766
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological interventions for promoting smoking cessation during pregnancy.
Claire R; Chamberlain C; Davey MA; Cooper SE; Berlin I; Leonardi-Bee J; Coleman T
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD010078. PubMed ID: 32129504
[TBL] [Abstract][Full Text] [Related]
55. Bupropion increases activation in nucleus accumbens during anticipation of monetary reward.
Ikeda Y; Funayama T; Tateno A; Fukayama H; Okubo Y; Suzuki H
Psychopharmacology (Berl); 2019 Dec; 236(12):3655-3665. PubMed ID: 31342097
[TBL] [Abstract][Full Text] [Related]
56. Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.
Marton S; González B; Rodríguez-Bottero S; Miquel E; Martínez-Palma L; Pazos M; Prieto JP; Rodríguez P; Sames D; Seoane G; Scorza C; Cassina P; Carrera I
Front Pharmacol; 2019; 10():193. PubMed ID: 30890941
[TBL] [Abstract][Full Text] [Related]
57. Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.
Pintarelli G; Galvan A; Pozzi P; Noci S; Pasetti G; Sala F; Pastorino U; Boffi R; Colombo F
Sci Rep; 2017 Dec; 7(1):16730. PubMed ID: 29196725
[TBL] [Abstract][Full Text] [Related]
58. Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.
Dauvermann MR; Lee G; Dawson N
Br J Pharmacol; 2017 Oct; 174(19):3136-3160. PubMed ID: 28626937
[TBL] [Abstract][Full Text] [Related]
59. High-Throughput Patch Clamp Screening in Human α6-Containing Nicotinic Acetylcholine Receptors.
Armstrong LC; Kirsch GE; Fedorov NB; Wu C; Kuryshev YA; Sewell AL; Liu Z; Motter AL; Leggett CS; Orr MS
SLAS Discov; 2017 Jul; 22(6):686-695. PubMed ID: 28298165
[TBL] [Abstract][Full Text] [Related]
60. The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors.
Pandhare A; Pappu AS; Wilms H; Blanton MP; Jansen M
Neuropharmacology; 2017 Feb; 113(Pt A):89-99. PubMed ID: 27671323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
